Questions about testing, chloroquine toxicity, duration of immunity and reinfection, and what to expect next are gripping the US as the novel coronavirus spreads. JAMA Associate Editor Preeti Malani, MD, professor of medicine and Chief Health Officer at the University of Michigan, discusses recent developments in a live conversation with JAMA Editor in Chief Howard Bauchner. Recorded on April 6, 2020.

US states are taking the lead in managing the COVID-19 pandemic. What can state governors expect from the federal government and from the US Department of Health and Human Services? Governor Mike Leavitt from Leavitt Partners joins JAMA Editor Howard Bauchner, MD, in this live Q&A. Recorded April 8, 2020.

New York City coronavirus update from Mitchell Katz, MD, President and CEO of NYC Health + Hospitals, the largest municipal public health system in the United States. Recorded April 13, 2020.

JAMA Health Forum editors John Ayanian, MD, MPP, and Melinda Buntin, PhD, discuss changes in US health care and health policy driven by the coronavirus pandemic. Recorded April 16, 2020.

Anne Schuchat, MD, Principal Deputy Director of the Centers for Disease Control and Prevention (CDC), discusses evolution of CDC guidance and latest developments in the COVID-19 pandemic. Recorded Friday May 1, 2020.

Ong, Jamie Wan Ling, author

With the emergence of coronavirus disease 2019 (COVID-19) as a global pandemic, individuals with preexisting chronic health conditions such as hypertension, diabetes, and cardiovascular disease have been identified as particularly vulnerable. These patients are also more likely than the general population to be taking angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that causes COVID-19 gains entry into cells via binding to the angiotensin-converting enzyme 2 (ACE2) receptor, concerns have been raised that these therapies might facilitate the transmission of the virus or affect outcomes adversely. Given that ACEI and ARB therapies are known to provide benefit for the underlying conditions treated, stopping ACEI/ARB therapy carries risks. Moreover, local inactivation of the renin-angiotensin-aldosterone system may have protective effects against the development and progression of acute lung failure. In the absence of clinical evidence of benefit or risk of ACEIs/ARBs, current societal statements recommend against discontinuing these drugs other than for standard clinical indications. Robust clinical data are needed to clarify the effect of ACEIs/ARBs on SARS-CoV-2 infection.

From advisories and warnings to smart witticisms, brands across categories are reaching out to consumers over the shadow of Covid-19

India Inc has embraced remote working because of a health scare. But there are important lessons on enabling infrastructure, managing remote teams and ensuring productivity...

The medicinal soap brand is seeing a sharp spurt in demand across the country

Google, Twitter, TikTok, Facebook team up with global health agencies and governments to put up the guardrails on the fake trail

The bank's board of directors has approved a loan to India to strengthen the preparedness of the country's national health system

Sources say the Centre has asked RBI to do whatever to keep yields in check, which may result in massive secondary market bond purchases